New cases of a dangerous, drug-resistant fungus have been identified in at least two states' hospital systems.

Lyell Therapeutics and Rakuten Medical all reached the $1 billion valuation mark. Some significant changes happened in 2019, with Auris Health getting bought by Johnson & Johnson for $3.4 billion ...

Johnson & Johnson’s rumoured interest in Auris Health has been confirmed with a $3.3 billion buyout deal that boosts the group’s position in the fast-growing surgical robotics market.

Johnson & Johnson MedTech has secured an FDA clearance for new artificial intelligence-powered guidance systems to support ...

In a retrospective study, researchers found a 2,200% increase in clinical Candida auris infections at Miami-based Jackson ...

C. auris is considered an urgent public health threat due to its resistance to multiple antifungal treatments and ability to spread quickly in healthcare settings, particularly among ...

C. auris is also known to spread in hospitals and other health care facilities. The team wondered if it might be prevalent in nursing homes, as well. To find out, they collected samples from ...

Other key players in the industry include Auris Health Inc. and Ethicon Endo Surgery Inc. Key Questions Answered in the Global Laparoscopy Devices Patent Landscape Report ...

Discover how new global guidelines aim to combat the rising threat of Candida infections with updated treatments and ...

A health task force has been set up to study this case more closely and prevent the fungus from spreading, the ministry said. The first Candida auris case in Britain was in 2013 and in the United ...

auris. The authors propose that long-term skin ... to avoid spreading these drug-resistant pathogens throughout health-care systems. A gut fungus protects mice against parasitic worms but ...